DENVER, CO - (NewMediaWire) - March 14, 2019 - Phoenix Life Sciences International Limited (OTC: PLSI) (“Phoenix Life”, the “Company”), an international adaptive healthcare solutions company, today announced that it has filed its Form 10-K Annual Reports, including audited financial reports, with the Securities and Exchange Commission (“SEC”) for the 2015 and 2016 fiscal years as part of the merger and consolidation completed at the end of 2018.
Phoenix Life was created through a consolidation of multiple domestic and international businesses. As final audits are being completed for the 2017 and 2018 fiscal years, corresponding 10-K Annual Reports will likewise be filed, providing prospective and current shareholders with current reporting.
Moving forward, Phoenix Life intends to maintain a fully reporting status with the SEC. This reporting status combined with OTC Markets requirements for maintaining an OTCQB listing are intended to provide the investing public with full transparency and greater market liquidity.
Following completion of bringing the Company current in its reporting, Phoenix Life intends to complete a significant capital placement to fund out company operations in the United States, Australia and the South Pacific, including Vanuatu and subsequently apply for listing on the NASDAQ.
“Phoenix Life is committed to maintaining the high level of corporate and financial disclosures required to provide existing and potential shareholders with full transparency, while providing greater access to capital for the Company and greater levels of market liquidity for our investors,” said Martin Tindall, CEO and Founder of Phoenix Life.
The Company is quickly advancing its international expansion efforts and just announced the groundbreaking of the first of a National Network of Community Clinics and Dispensing Pharmacies for the treatment of diabetes in the Republic of Vanuatu last week. “It is great to see Phoenix Life’s milestones being achieved consistently and we look forward to achieving much more in 2019 and beyond,” continued Tindall.
To learn more about Phoenix Life Sciences International, please visit https://phoenixlife.co/.
About Phoenix Life Sciences International Limited
Phoenix Life Sciences International Limited is an adaptive healthcare solutions company. Our business is to advance research and integrate programs and manufacturing of products that target and treat diabetes, pain, cancer, and address psychological, gastrointestinal, autoimmune, neurological and sleep disorders. We strive to create partnerships and integrate these programs for human health into communities worldwide as part of our Global Health Initiative.
Information contained in this press release regarding Phoenix Life Sciences International, Limited and its subsidiaries, (the “Companies”) may constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words “plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”, “expect”, “should”, “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to the Companies herein are expressly qualified in their entirety by the above-mentioned cautionary statement. The Companies disclaim any obligation to update forward-looking statements contained in this press release, except as may be required by law.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and therefore the products sold by Phoenix Life Sciences International are not available in the U.S.
Phoenix Life Sciences International does not sell or distribute any products in the United States that are in violation of the United States Controlled Substances Act (US.CSA). This company does not grow, sell, and distribute cannabis-based products in the United States and is solely involved with the legal distribution of medical cannabis-based products within certain international markets outside of the United States.
Investor Contact: Phone: 1.888.717.5655 or international +1.720.699.7222 E-mail: email@example.com Media Contact: Kathryn Reinhardt CMW Media Kathryn@cmwmedia.com 619-972-3089